Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay
Not Applicable
Completed
- Conditions
- Sunscreen Agents
- Interventions
- Drug: BAY 987519Drug: SPF 15 Control
- Registration Number
- NCT02872233
- Lead Sponsor
- Bayer
- Brief Summary
Evaluation of the effectiveness of a sunscreen product by determining its Sun Protection Factor (SPF) on the skin of human subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Male or female of an age of 18 to 70 years inclusive;
- Fitzpatrick Skin Type I, II and/or III for SPF testing;
- Good health as determined from the CRO Subject History Form (SHF);
- Signed and dated Informed Consent Form;
- Signed and dated Health Insurance Portability and Accountability Act (HIPAA) Form;
- An unambiguous minimal erythema dose (MED).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SPF evaluation BAY 987519 Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing. SPF evaluation SPF 15 Control Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
- Primary Outcome Measures
Name Time Method Evaluation of 2 hours water resistant SPF 16-24 h post exposure ISO/COLIPA Sun Protection FactorTest Method.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does BAY 987519 utilize to enhance UV protection in sunscreen formulations?
How does the SPF of BAY 987519 compare to standard-of-care sunscreen agents in clinical trials?
Are there specific biomarkers that correlate with improved UVA protection when using BAY 987519?
What adverse events are associated with BAY 987519 application and how are they managed in clinical settings?
What are the potential combination strategies involving BAY 987519 and other photoprotective compounds in sunscreen development?